Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Suspended 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Plasma cell 2Lymphoid 2Head & Neck 2Genitourinary 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Glioma 2Glioblastoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiotherapy 63Temozolomide 59Magnetic Resonance Spectroscopy 46Carboplatin 40Cyclophosphamide 39Vincristine 35Specimen Handling 28Etoposide 26Cisplatin 26Radiation 22Chemotherapy, Adjuvant 22Filgrastim 20Bevacizumab 20Doxorubicin 18Peripheral Blood Stem Cell Transplantation 17Biopsy 17Vorinostat 16Surgical Procedures, Operative 14Melphalan 13Immunoglobulin G 13Disulfides 13Radiotherapy, Conformal 12Isotretinoin 12Erlotinib Hydrochloride 12X-Rays 11Nivolumab 11Irinotecan 11Carmustine 11aldesleukin 10Topotecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × relatlimab × CNS × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06325683 2026-06-03

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

NCT03493932 2024-07-24

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
21 enrolled 9 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡